-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology qPCR Platform
Author:
InnoModels
Release time:
2024-09-13
In today's era of rapid biotechnology development, the research and development of oncology drugs are facing unprecedented challenges and opportunities. In order to more accurately assess drug effects, optimize drug structure and promote early drug release, scientists are constantly seeking more efficient and precise detection methods. InnoModels Biotechnology (Beijing) Co., Ltd. provides strong technical support for oncology drug research and development with its advanced qPCR (real-time quantitative polymerase chain reaction) platform.
qPCR platform: highly sensitive and precise
The qPCR platform is unique in the field of nucleic acid detection due to its high sensitivity and precision. The platform is capable of detecting very low levels of target nucleic acids, providing accurate quantitative data, which is critical for evaluating the impact of tumor drugs on the expression of target genes. Especially for nucleic acid coupled drugs and mRNA drugs, the qPCR platform is specifically designed to ensure high efficiency and specificity of the assay to accurately assess the activity and effect of the drug.
Technical Advantage: High Efficiency and Flexibility
InnoModels Bio's qPCR platform is not only highly sensitive and accurate, but also has high throughput and flexibility. The platform supports simultaneous testing of multiple samples, which greatly accelerates the drug development process. In addition, the platform can be customized to meet the diverse needs of scientists in the research process. This one-stop service, from sample processing to data analysis, provides researchers with comprehensive support and greatly improves research efficiency and accuracy.
Drug Effect Evaluation and Mechanism Research
Through the qPCR platform, researchers can measure the expression of target genes to accurately assess the activity and effect of drugs. This is crucial for the development of oncology drugs, as the effectiveness of a drug directly determines whether it can be successfully applied in the clinic. In addition, the qPCR platform helps to delve into the mechanism of action of nucleic acid-coupled drugs and mRNA drugs, providing direction for drug optimization. This in-depth understanding helps to discover the potential targets of the drugs and improve their relevance and effectiveness.

Safety Assessment and Clinical Application
In addition to evaluating the activity and efficacy of a drug, the qPCR platform also assesses the potential toxicity and safety of a drug by detecting the expression of relevant marker genes. This is important to ensure the safety of drugs and reduce side effects. Through the qPCR platform, researchers can identify potential safety issues at the early stage of drug development, so as to adjust the direction of research in a timely manner and avoid unnecessary waste and risk.
InnoModels Biotechnology: Deeply engaged in oncology drug discovery and development
Founded by scientists from Novo Nordisk China R&D Center, Sino-US Champion and Shanghai Jiao Tong University Institute of Immunology, InnoModels Biotechnology (Beijing) Co., Ltd. owns a stable platform of humanized immune system mouse model (HIS) and human tumor xenograft platform (PDX) in China. The company focuses on oncology and tumor immuno pharmacodynamics CRO services, translational medicine research services, and individualized medicine, and is committed to providing a new generation of experimental animal models close to the clinic for the research and development of oncology and tumor immunotherapy.
As one of the company's important R&D tools, InnoModels' qPCR platform has been widely used in the research and development of oncology drugs. Through the cooperation with many famous pharmaceutical companies and research institutes at home and abroad, InnoModels Biotechnology has achieved remarkable results in the field of oncology drug research and development, and made positive contributions to the development of oncology treatment.
Conclusion
With its highly sensitive, precise, efficient and flexible features, InnoModels' qPCR platform plays an important role in the field of tumor drug discovery and development. Through the application of this platform, researchers can more accurately assess the activity and effect of drugs, deeply study the mechanism of action of drugs, and evaluate the potential toxicity and safety of drugs, providing strong technical support for the development of tumor drugs. In the future, with the continuous advancement of technology and the expansion of application fields, the qPCR platform of InnoModels Biotechnology will play an important role in more fields and make greater contributions to the cause of human health.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd